Novo Nordisk remains a dominant business with a strong pipeline, and current multiples are low enough to justify a buy. Read my latest analysis of NVO stock.
The names keep changing for the Indiana Fever, and so has the result: They're as hot as they've been all season, and this is their best year 2015. Caitlin Clark has played just 13 games, but the Fever ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback